Sigma-1 receptor modulation fine-tunes KV1 - Vera-Zambrano A, Baena-Nuevo M, Rinné S, Villegas-Esguevillas M, Barreira B, Telli G, de Benito-Bueno A, Blázquez JA, Climent B, Pérez-Vizcaino F, Valenzuela C, Decher N, Gonzalez T, Cogolludo A (Pharmacological Research, 2023)

Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases - M Chaparro; D Acosta; C Rodriguez; F Mesonero; M Vicuna; M Barreiro-de Acosta; A Fernandez-Clotet; A Hernandez Martinez; M Arroyo; I Vera; A Ruiz-Cerulla; B Sicilia; et al. (Journal Of Crohns & Colitis, 2023)

Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry. - M Calafat Sard; I Pascual; P Nos; J Barrio; A Gutiérrez; MD Martin-Arranz; E Ricart; F Gomollon; M Sierra Ausin; JM Huguet; J Guardiola; I Vera; et al. (Journal Of Crohns & Colitis, 2023)

Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study - Casanova, MJ; NantFs, O; VarTla, P; Vela-González, M; Rivero, M; Sierra-Gabarda, O; Riestra, S; Barreiro-de Acosta, M; Martín-Rodríguez, MD; Gargallo-Puyuelo, CJ; Reygosa, C; Muñoz, R; et al. (Alimentary Pharmacology & Therapeutics, 2023)

Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII) - Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, P Gisbert J, Mesonero F, Benítez O, Taxonera C, Ponferrada-Díaz Á, Piqueras M, J Lucendo A, Caballol B, Mañosa M, Martínez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Manceñido N, Martínez-Pérez T, López A, Rodríguez-Gutiérrez C, García-López S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de Acosta M, Sicilia B, Barrio J, Pérez Calle JL, Busquets D, Pérez-Martínez I, Navarro-Llavat M, Hernández V, Argüelles-Arias F, Ramírez Esteso F, Meijide S, Ramos L, Gomollón F, Muñoz F, Suris G, Ortiz de Zarate J, Huguet JM, Llaó J, García-Sepulcre MF, Sierra M, Durà M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutiérrez A, Varela P, Rull N, Gilabert P, Hernández-Camba A, Brotons A, Ginard D, Sesé E, Carpio D, Aceituno M, Cabriada JL, González-Lama Y, Jiménez L, Chaparro M, López-San Román A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastián S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galán H, Pajares R, Olcina P, Manzano P, Domènech E, Esteve M, On Behalf Of The Eneida Registry Of Geteccu (Journal Of Clinical Medicine, 2022)

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (vol 10, 2885, 2021) - Chaparro M, Garre A, Núñez Ortiz A, Diz-Lois Palomares MT, Rodríguez C, Riestra S, Vela M, Benítez JM, Fernández Salgado E, Sánchez Rodríguez E, Hernández V, Ferreiro-Iglesias R, Ponferrada Díaz Á, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Varela Trastoy P, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarri A, Gomollón F, Guerra Del Río E, Piñero C, Casanova MJ, Spicakova K, Ortiz de Zarate J, Torrella Cortés E, Gutiérrez A, Alonso-Galán H, Hernández-Martínez Á, Marrero JM, Lorente Poyatos R, Calafat M, Martí Romero L, Robledo P, Bosch O, Jiménez N, Esteve Comas M, Duque JM, Fuentes Coronel AM, Josefa Sampedro M, Sesé Abizanda E, Herreros Martínez B, Pozzati L, Fernández Rosáenz H, Crespo Suarez B, López Serrano P, Lucendo AJ, Muñoz Vicente M, Bermejo F, Ramírez Palanca JJ, Menacho M, Carmona A, Camargo R, Torra Alsina S, Maroto N, Nerín de la Puerta J, Castro E, Marín-Jiménez I, Botella B, Sapiña A, Cruz N, Forcelledo JLF, Bouhmidi A, Castaño-Milla C, Opio V, Nicolás I, Kutz M, Abraldes Bechiarelli A, Gordillo J, Ber Y, Torres Domínguez Y, Novella Durán MT, Rodríguez Mondéjar S, Martínez-Cerezo FJ, Kolle L, Sabat M, Ledezma C, Iyo E, Roncero Ó, Irisarri R, Lluis L, Blázquez Gómez I, Zapata EM, José Alcalá M, Martínez Pascual C, Montealegre M, Mata L, Monrobel A, Hernández Camba A, Hernández L, Tejada M, Mir A, Galve ML, Soler M, Hervías D, Gómez-Valero JA, Barreiro-de Acosta M, Rodríguez-Artalejo F, García-Esquinas E, Gisbert JP, The EpidemIBD Study Group Of Geteccu (Journal Of Clinical Medicine, 2022)

Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity - Guijarro LG, Cano-Martínez D, Toledo-Lobo MV, Ruiz-Llorente L, Chaparro M, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-Sánchez V, Marín-Jiménez I, Barreiro-de Acosta M, Vera I, Martín-Arranz MD, Mesonero F, Sempere L, Gomollón F, Hinojosa J, Zoullas S, Monserrat J, Menor-Salvan C, Alvarez-Mon M, Gisbert JP, Ortega MA, Hernández-Breijo B (Biomedicines, 2022)

Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients - Gutiérrez A; Zapater P; Ricart E; González-Vivó M; Gordillo J; Olivares D; Vera I; Mañosa M; Gisbert JP; Aguas M; Sánchez-Rodríguez E; Bosca-Watts M; et al. (Frontiers Of Medicine, 2022)

Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients? - Ferreiro Iglesias, R.; Porto Silva, M. S.; Marin, S.; Casanova, M. J.; Manosa, M.; Gonzalez-Munoza, C.; de Francisco, R.; Caballol, B.; Arias, L.; Piqueras, M.; Zabana, Y.; Rivero, M.; et al. (Journal Of Crohns & Colitis, 2022)

Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study - Julià A, Martínez-Mateu SH, Domènech E, Cañete JD, Ferrándiz C, Tornero J, Gisbert JP, Fernández-Nebro A, Daudén E, Barreiro-de Acosta M, Pérez C, Queiró R, López-Longo FJ, Carazo JLS, Mendoza JL, Alpéri M, Montilla C, Venegas JJP, Muñoz F, Castañeda S, Aterido A, Lasanta ML, Marsal S, IMID Consortium (European Journal of Clinical Nutrition, 2021)

Follow-Up Study Confirms the Presence of Gastric Cancer DNA Methylation Hallmarks in High-Risk Precursor Lesions - Gomez, Antonio; Pato, Miguel L.; Bujanda, Luis; Sala, Nuria; Companioni, Osmel; Cosme, Angel; Tufano, Martina; Hanly, David J.; Garcia, Nadia; Sanz-Anquela, Jose Miguel; Gisbert, Javier P.; Lopez, Consuelo; et al. (Cancers, 2021)

Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-?: results from the ENEIDA registry - Mesonero F, Castro-Poceiro J, Benítez JM, Camps B, Iborra M, López-García A, Torres P, Esteve M, Tosca J, Bertoletti F, Almela P, Calvet X, Vera I, Bujanda L, Gomollón F, Rodríguez C, Antolín B, Busquets D, Hernández A, Rivero M, Monfort I Miquel D, Castaño-García A, Gisbert JP, Domènech E, López-Sanromán A, ENEIDA Project of GETECCU (Alimentary Pharmacology & Therapeutics, 2021)

Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma - Gómez León N; Aguado Bueno B; Herreros Pérez M; León Ramírez LF; Alegre A; Colletti PM; Rubello D; Carreras JL; Delgado Bolton RC (Clinical Nuclear Medicine, 2021)

Poor Sensitivity of Fecal Gluten Immunogenic Peptides and Serum Antibodies to Detect Duodenal Mucosal Damage in Celiac Disease Monitoring - Laserna-Mendieta, Emilio J.; Casanova, Maria Jose; Arias, Angel; Arias-Gonzalez, Laura; Majano, Pedro; Mate, Luis Alberto; Gordillo-Velez, Carlos Humberto; Jimenez, Mirella; Angueira, Teresa; Tebar-Romero, Emilia; Carrillo-Ramos, Maria Jesus; Tejero-Bustos, Maria angeles; et al. (Nutrients, 2021)

The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU - Chaparro, M; Donday, MG; Abad-Santos, F; de Carpi, FJM; Macia-Martinez, MA; Montero, D; Acosta, D; Brenes, Y; Gisbert, JP (Therapeutic Advances In Gastroenterology, 2021)

Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial - Chaparro M, Gordillo J, Domènech E, Esteve M, Barreiro-de Acosta M, Villoria A, Iglesias-Flores E, Blasi M, Naves JE, Benítez O, Nieto L, Calvet X, García-Sánchez V, Villagrasa JR, Marin AC, Donday MG, Abad-Santos F, Gisbert JP (American Journal Of Gastroenterology, 2020)

Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU - M Chaparro; M Barreiro-de Acosta; J Benítez; J Cabriada; M Casanova; D Ceballos; M Esteve; H Fernández; D Ginard; F Gomollón; R Lorente; P Nos; et al. (Journal Of Crohns & Colitis, 2020)

EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain - M Chaparro; M Barreiro-de Acosta; JM Benítez; JL Cabriada4; MJ Casanova; Dl Ceballos; M Esteve; H Fernández; D Ginard; F Gomollón; R Lorente; P Nos; et al. (Therapeutic Advances In Gastroenterology, 2019)

Launch and preliminary analysis of Hospital de La Princesas inter-specialists biological therapies unit - Álvaro Gracia, J M; Arredondo, Miguel; Daudén Tello, Esteban; Meca-Lallana, Virginia; Morell Baladrón, Alberto; Pérez Gisbert, Javier; Fernández-Jiménez, Guillermo; García de Vicuña, Rosario; Aspa, Francisco Javier; García de Yébenes, María Jesús; Carmona Ortells, Loreto (Reumatologia Clinica, 2019)

Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract - Fernandez-Tome, Samuel; Montalban-Arques, Ana; Diaz-Guerra, Alba; Galvan-Roman, Jose M; Marin, Alicia C; Mora-Gutierrez, Irene; Ortega Moreno, Lorena; Santander, Cecilio; Sanchez, Borja; Chaparro, Maria; Gisbert, Javier P; Bernardo, David (Journal Of Functional Foods, 2019)

Biosimilar and interchangeable: Inseparable scientific concepts? - de Mora F., Balsa A., Cornide-Santos M., Carrascosa J.M., Marsal S., P. Gisbert J., Abad M.A., F. Duarte R., Wiechmann M., Martínez R. (British Journal Of Clinical Pharmacology, 2019)

Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease - M Chaparro; A Aterido; I Guerra; M Iborra; J Cabriada; L Bujanda; C Taxonera; V García-Sánchez; I Marín-Jiménez; M Barreiro-de Acosta; I Vera; M Martín-Arranz; et al. (Therapeutic Advances In Gastroenterology, 2019)

Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial - McNicholl AG, Molina-Infante J, Lucendo AJ, Calleja JL, Pérez-Aisa Á, Modolell I, Aldeguer X, Calafat M, Comino L, Ramas M, Callejo Á, Badiola C, Serra J, Gisbert JP (Helicobacter, 2018)

Bifidobacterium longum subsp longum microbiota-secreted bioactive peptide as a novel immunomodulatory compound in the human gastrointestinal tract - S Fernández Tomé; A Montalbán-Arqués; A Díaz-Guerra; JM Galván Román; AC Marín; I Mora-Gutiérrez; C Santander; B Sánchez; M Chaparro; JP Gisbert; D Bernardo (Journal Of Crohns & Colitis, 2018)

Role of tetraspanin CD9 in murine experimental colitis - Garcia Arroyo, Alicia (Autor o Coautor); Perez Gisbert, Francisco Javier (Autor o Coautor); Fresno Escudero, Manuel (Autor o Coautor); Francisco Sánchez Madrid (Director) Doctorando: María Laura Saiz Alvarez (2018)

Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la monitorización, prevención y tratamiento de la recurrencia posquirúrgica en la enfermedad de Crohn - Domènech, Eugeni; López San Román, Antonio; Nos Mateu, Pilar; Vera Mendoza, María Isabel; Chaparro Sánchez, María; Esteve, María; Pérez Gisbert, Javier; Mañosa, Míriam (Gastroenterologia Y Hepatologia, 2017)

Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. - Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, Gisbert JP (American Journal Of Gastroenterology, 2017)

Colitis ulcerosa asociada a pancreatitis autoinmune, sialoadenitis y vasculitis leucocitoclástica - Lindo Ricce, Mayra; Martín Domínguez, Verónica; Real Martínez, Yolanda; González Moreno, Leticia; Martínez, Constanza; Aragües Montañes, Maximiliano; Gordillo Vélez, Carlos Humberto; Pérez Gisbert, Javier (Gastroenterologia y Hepatologia, 2016)

Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease - Casanova, MJ; Chaparro, M; Valenzuela, C; Cisneros, C; Gisbert, JP (WORLD JOURNAL OF GASTROENTEROLOGY, 2015)

Evolución de la osteopenia y la osteoporosis a lo largo de 5 años en pacientes con enfermedad inflamatoria intestinal - Perez Gisbert, Francisco Javier (Director) Doctorando: F Casals (2015)

EFFECT OF CHONDROITIN SULPHATE ON PRO-INFLAMMATORY MEDIATORS AND DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - Santos, FA; Linares, PM; Chaparro, M; Algaba, A; Martínez, MR; Arza, IM; Ochoa, D; José, FBS; Gisbert, J (Basic & Clinical Pharmacology & Toxicology, 2014)

Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice - A G McNicholl, A C Marín, J Molina-Infante, M Castro-Fernández; J Barrio, J Ducons, X Calvet, C de la Coba, M Montoro, F Bory, A Pérez-Aisa; M Forné, M Ramas, R Millán, P Araguren, P García-Iglesias, B Belloc,X Bessa; E Sainz, J L Gisbert, E Lamas, E Marcos, M I Moreno,F Abad-Santosand J P Gisbert (Gut, 2014)

Infliximab en el tratamiento de la enfermedad de Crohn gastroduodenal resistente - Rodríguez Grau, María del Carmen; Chaparro Sánchez, María; Díaz de Tudanca, Raquel; Pérez Gisbert, Javier (Gastroenterologia Y Hepatologia, 2014)

Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de fármacos antifactor de necrosis tumoral ? en la enfermedad inflamatoria intestinal (2013) - Cabriada Nuño, José Luis; Vera Mendoza, María Isabel; Domènech, Eugeni; Barreiro de Acosta, M; Esteve Comas, María; Pérez Gisbert, Javier; Julia, Panés; Gomollón García, Fernando (Gastroenterologia Y Hepatologia, 2013)

Identification of the substrates of the protease mt1? mmp in tnf??stimulated endothelial cells by quantitative proteomics. Analysis of their potencial use as biomarkers in inflammatory bowel disease - Perez Gisbert, Francisco Javier (Autor o Coautor); Jimenez Cuenca, Benilde (Autor o Coautor); Alicia García Arroyo (Director); Garcia Arroyo, Alicia (Autor o Coautor); Amparo Cano (Director) Doctorando: Agnieszka Koziol (2013)

Prevalence of Different Immune-Mediated Inflammatory Diseases in Patients With Inflammatory Bowel Disease. AQUILES study - I Marín-Jiménez, F Gómez, JP Gisbert, JL Pérez-Calle, M Luján, J Gordillo; I Moral, M Andreu, L Cea Calvo, R García de Vicuña, F Vanaclocha, C Romero (Inflammatory Bowel Diseases, 2012)

Utility of assessing thiopurine S-methyltransferase polymorphisms before azathioprine therapy - Abad Santos, Francisco; Perez Gisbert, Francisco Javier (Current Drug Metabolism, 2012)

Validation of a Genotyping Method for Analysis of TPMT Polymorphisms - Román, M; Cabaleiro, T; Ochoa, D; Novalbos, J; Chaparro, M; Gisbert, JP; Abad-Santos, F (Clinical Therapeutics, 2012)

Evaluation of liver fibrosis by transient elastography in methotrexate treated patients - Barbero-Villares, A; Mendoza, J; Trapero-Marugan, M; Gonzalez-Alvaro, I; Daudén, E; Gisbert, JP; Moreno-Otero, R (Medicina Clinica, 2011)

Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohns disease. The Madrid experience - Fortea Ormaechea, José Ignacio; González Lama, Yago; Casis Herce, Begoña; Chaparro Sánchez, María; López Serrano, Pilar; van Domselaar, Manuel; Bermejo San José, Fernando; Pajares Villarroya, Ramón; Ponferrada Díaz, Ángel; Vera Mendoza, María Isabel; Martínez Montiel, Pilar; Pérez Gisbert, Javier; et al. (Gastroenterologia Y Hepatologia, 2011)

Recommendations for the management of influenza A (H1N1) in rheumatic patients with immunosuppression - García de Vicuña R; Padilla B; Carreño L; Muñoz Fernández S; Martín Mola E; Gómez-Reino J; Martínez Taboada V; López Sanromán A; Pérez Gisbert J; Díaz González F; Hinojosa del Val J; Bouza E; et al. (Reumatologia Clinica, 2010)

Eficacia de la levadura Saccharomyces Boulardii como probiótico en el tratamiento de las enfermedades digestivas - Galicia, Ignacio; Abad Santos, Francisco; Pérez Gisbert, Javier; García López, Manuela (Actualidad En Farmacología Y Terapéutica, 2010)

Systematic review: Hepatitis-associated aplastic anaemia - A syndrome associated with abnormal immunological function - Gonzalez-Casas, R; Garcia-Buey, L; Jones, EA; Gisbert, JP; Moreno-Otero, R (ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009)

Accuracy of Computed Tomographic Colonography for the Detection of Polyps and Colorectal Tumors: A Systematic Review and Meta-Analysis - Chaparro, M; Gisbert, JP; del Campo, L; Cantero, J; Maté, J (Digestion, 2009)

Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis - Gómez-Dominguez, E; Mendoza, J; García-Buey, L; Trapero, M; Gisbert, JP; Jones, EA; Moreno-Otero, R (ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008)

Open-label infliximab therapy in Crohn´s disease: a long-term multicenter study of efficacy, safety and predictors of response - Y González-Lama, A López-SanRomán, I Marín-Jiménez, B Casis, I Vera, F Bermejo; J Pérez-Calle, C Taxonera, F Martinez-Silva, L Menchén, P Martínez-Montiel, M Calvo, JA Carneros; P López, JL Mendoza, JM Milicua, A Huerta, F Sánchez, L Abreu, N López-Palacios, J Maté; JP Gisbert On behalf of the Group for the Study of Inflammatory Bowel Diseases from Madrid (Gastroenterologia Y Hepatologia, 2008)

Computed tomography colonography compared with conventional colonoscopy for the detection of colorectal polyps - Maté Jiménez, José; Campo Val, Lourdes del; Moreno Otero, Ricardo; Chaparro Sánchez, María; Barbero Villares, Antonio; Cantero Perona, José; Khorrami, Sam (Gastroenterologia Y Hepatologia, 2007)

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients - Gómez-Domínguez, E; Gisbert, JP; Moreno-Monteagudo, JA; García-Buey, L; Moreno-Otero, R (ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006)

Lamivudine response of IgM anti-HBc chronic hepatitis B patients [1] - Gómez-Domínguez, E; García-Buey, L; Gisbert, JP; Moreno-Otero, R (ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006)

Comparison of gastric endoscopic lesions and tolerability to ibuprofen and ibuprofen-arginate in healthy subjects - Gisbert, JP; Abad-Santos, F; Novalbos, J; Khorrami, S; Gallego-Sandin, S; Rosado, A; Gálvez-Múgica, MA; Pajares, JM (Journal Of Clinical Gastroenterology, 2005)

Regression of lymphoproliferative disorders after treatment for hepatitis C infection? a systematic review - JP Gisbert, L García-Buey, JM Pajares, R Moreno-Otero (Gastroenterology, 2005)

Analysis of angiogenesis soluble factors (asf) in chronic hepatitis C (chc) patients - X Salcedo-Mora, P Sanz-Cameno, J Medina, S Martín-Vílchez, L García-Buey; M Trapero, E Gómez-Domínguez, J A Moreno-Monteagudo, M J Borque; S Rubio, J Mendoza, J Legido, JP Gisbert, R Moreno-Otero (Gastroenterology, 2005)

Systematic review: Regression of lymphoproliferative disorders after treatment for hepatitis C infection - Gisbert, JP; García-Buey, L; Pajares, JM; Moreno-Otero, R (ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005)

Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: correlation with endoscopic lesions and adverse reactions - Gallego-Sandín, S; Novalbos, J; Rosado, A; Gisbert, JP; Gálvez-Múgica, MA; García, AG; Pajares, JM; Abad-Santos, F (Digestive Diseases And Sciences, 2004)

Hepatocellular carcinoma risk in patients with porphyria cutanea tarda - Gisbert, JP; García-Buey, L; Alonso, A; Rubio, S; Hernández, A; Pajares, JM; García-Díez, A; Moreno-Otero, R (European Journal Of Gastroenterology & Hepatology, 2004)

Absence of hepatitis C virus infection among patients with lymphoproliferative disorders in northern India - Reply - Gisbert, JP; García-Buey, L; Pajares, JM; Moreno-Otero, R (Gastroenterology, 2004)

Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma. Systematic review and meta-analysis - JP Gisbert, L García-Buey, JM Pajares, R Moreno-Otero (Gastroenterology, 2004)

The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma - Gisbert, JP; García-Buey, L; Arranz, R; Blas, C; Pinilla, I; Khorrami, S; Acevedo, A; Borque, MJ; Pajares, JM; Fernández-Rañada, JM; Moreno-Otero, R (EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004)

Predictors of response to infliximab in patients with fistulizing Crohn's disease - Perez Gisbert, Francisco Javier; Mate Jimenez, Jose; Froilan Torres, Maria Consuelo; Luna-Chadid, M; Calle, Jlp; Mendoza, JL; Vera, MI; Bermejo, AF; Sanchez, F; San Roman, AL; Froilan, C; Gonzalez-Lara, V; et al. (Revista Espanola De Enfermedades Digestivas, 2004)

Helicobacter pylori and perforated peptic ulcer. Prevalence of the infection and role of non-steroidal anti-inflammatory drugs - Gisbert, JP; Legido, J; García-Sanz, I; Pajares, JM (Digestive And Liver Disease, 2004)

Absence of Hepatitis C Virus Infection among Patients with Lymphoproliferative Disorders in Northern India [7] (multiple letters) - Varma S; Dhiman RK; Srivastava D; Malhotra P; Chawla Y; Gisbert JP; García-Buey L; Pajares JM; Moreno-Otero R (Gastroenterology, 2004)

Prevalence of hepatitis C virus infection in porphyria cutanea tarda: Systematic review and meta-analysis - Gisbert, JP; García-Buey, L; Pajares, JM; Moreno-Otero, R (JOURNAL OF HEPATOLOGY, 2003)

INFLUENCE OF FUROSEMIDE ON THE ACIDIFICATION DISTURBANCES IN RENAL TUBULAR-ACIDOSIS - Garcia Puig J; Mateos Anton F; Anciones B; Grande C; Gilaquado A; Arnalich F; Barbado J; Vázquez J; Gisbert P; Martin P; Casares M; Riñón M; et al. (Revista Clinica Espanola, 1980)

A CONTINUACIÓN SE INCLUYEN ÚNICAMENTE LOS PROYECTOS COMPETITIVOS ACTIVOS EN LOS ÚLTIMOS 5 AÑOS - Perez Gisbert, Francisco Javier (Investigador/a)

PARTICIPACIÓN COMO INVESTIGADOR PRINCIPAL EN MÁS DE 50 CONTRATOS CON LA INDUSTRIA FARMACÉUTICA PARA EL DESARROLLO DE ESTUDIOS EN ENFERMEDAD INFLAMATORIA INTESTINAL DURANTE LOS ÚLTIMOS 5 AÑOS - Perez Gisbert, Francisco Javier (Participante)

>400 COMUNICACIONES PRESENTADAS A CONGRESOS NACIONALES E INTERNACIONALES EN LOS ÚLTIMOS 5 AÑOS - Perez Gisbert, Francisco Javier

Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions-Authors' reply. - García MJ; Gisbert JP; Chaparro M (Alimentary Pharmacology & Therapeutics, 2024)

Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry - Guerra, Ivan; Barros, Francisco; Chaparro, Maria; Benitez, Jose M; Benitez, Jose M; Martin-Arranz, Maria Dolores; de Francisco, Ruth; Piqueras, Marta; de Castro, Luisa; Carbajo, Ana Y; Carbajo, Ana Y; Bermejo, Fernando; et al. (Digestive Diseases, 2024)

Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management. - Huguet JM; Ferrer-Barceló L; Suárez P; Barcelo-Cerda S; Sempere J; Saracino IM; Fiorini G; Vaira D; Pérez-Aísa Á; Jonaitis L; Tepes B; Castro-Fernandez M; et al. (United European Gastroenterology Journal, 2024)

Efficacy, Effectiveness, and Safety of Ustekinumab for the Treatment of Ulcerative Colitis: A Systematic Review - Gisbert, JP; Parody-Rúa, E; Chaparro, M (Inflammatory Bowel Diseases, 2024)

Comparative Study Of The Effectiveness Of Vedolizumab Versus Ustekinumab After Anti-Tnf Failure In Crohn's Disease (Versus-Cd): Data From Eneida Registry - García MJ, Rivero M, Fernández-Clotet A, de Francisco R, Sicilia B, Mesonero F, de Castro ML, Casanova MJ, Bertoletti F, García-Alonso FJ, López-García A, Vicente R, Calvet X, Barreiro-de Acosta M, Ferrer Rosique J, Varela Trastoy P, Nuñez A, Ricart E, Riestra S, Arias García L, Rodríguez M, Arranz L, Pajares R, Mena R, Calafat M, Camo P, Bermejo F, Ponferrada Á, Madrigal RE, Llaó J, Sesé E, Sánchez E, Pineda Mariño JR, González Muñoza C, Carbajo López AY, Julián AB, Villoria Ferrer A, Baston-Rey I, Jara L, Almela P, Codesido L, de la Maza S, Leal C, Caballol B, Pérez-Martínez I, Vinuesa Campo R, Crespo J, Domènech E, Chaparro M, Gisbert JP, ENEIDA project of GETECCU (Journal Of Crohns & Colitis, 2024)

Adalimumab Clearance, rather than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and Endoscopically - Wright, EK; Chaparro, M; Gionchetti, P; Hamilton, AL; Schulberg, J; Gisbert, JP; Valerii, MC; Rizzello, F; De Cruz, P; Panetta, JC; Everts-van der Wind, A; Kamm, MA; et al. (Journal Of Crohns & Colitis, 2024)

De-escalation of biological treatment in inflammatory bowel disease: A comprehensive review - Gisbert, JP; Chaparro, M (Journal Of Crohns & Colitis, 2024)

Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance - Bujanda L; Nyssen OP; Ramos J; Bordin DS; Tepes B; Perez-Aisa A; Pavoni M; Castro-Fernandez M; Lerang F; Leja M; Rodrigo L; Rokkas T; et al. (American Journal Of Gastroenterology, 2024)

Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies - Ten Bokkel Huinink S; Thomassen D; Steyerberg EW; Pauwels RWM; Casanova MJ; Bouguen G; Mak JWY; Molnár T; Lobo AJ; Seidelin JB; Amiot A; D'Haens G; et al. (Journal Of Crohns & Colitis, 2024)

Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients - Aldars-García L; Gil-Redondo R; Embade N; Riestra S; Rivero M; Gutiérrez A; Rodríguez-Lago I; Fernández-Salazar L; Ceballos D; Manuel Benítez J; Aguas M; Baston-Rey I; et al. (Inflammatory Bowel Diseases, 2024)

Helicobacter pylori Eradication Treatment in Older Patients - Jonaitis P; Kupcinskas J; Gisbert JP; Jonaitis L (Drugs & Aging, 2024)

Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study) - García MJ; Riestra S; Amiot A; Julsgaard M; García de la Filia I; Calafat M; Aguas M; de la Peña L; Roig C; Caballol B; Casanova MJ; Farkas K; et al. (Alimentary Pharmacology & Therapeutics, 2024)

Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis - Rokkas T; Gisbert JP; Ekmektzoglou K; Dassopoulos T; Niv Y; O'Morain C (European Journal Of Gastroenterology & Hepatology, 2024)

PCD23/00075. Programa Sara Borrell Acción Estratégica en Salud. ISCIII. IP Senior Grupo Receptor - Perez Gisbert, Francisco Javier (Investigador/a) (2024)

PT23/00060. Unidades de Plataformas ISCIII de apoyo a la I+D+I en Biomedicina y Ciencias de la Salud de la AES. Miembro de la Unidad - Perez Gisbert, Francisco Javier (Investigador/a) (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis-Ready for revision? Authors' reply - García MJ; Gisbert JP; Chaparro M (Alimentary Pharmacology & Therapeutics, 2024)

Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry - Casas Deza D; Polo Cuadro C; de Francisco R; Vela González M; Bermejo F; Blanco I; de la Serna Á; Bujanda L; Bernal L; Rueda García JL; Gargallo-Puyuelo CJ; Fuentes-Valenzuela E; et al. (Journal Of Crohns & Colitis, 2024)

The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease - Müller-Ladner, U; Dignass, A; Gaffney, K; Jadon, D; Matucci-Cerinic, M; Lobaton, T; Carron, P; Gisbert, JP; Pande, I; Utzinger, M; Addison, J (Biodrugs, 2023)

Long Non-Coding RNA Signatures in the Ileum and Colon of Crohn?s Disease Patients and Effect of Anti-TNF-? Treatment on Their Modulation - Baldan-Martin, M; de Célix, CR; Orejudo, M; Moreno, LO; Fernández-Tomé, S; Soleto, I; Ramirez, C; Arroyo, R; Fernández, P; Santander, C; Moreno-Monteagudo, JA; Casanova, MJ; et al. (International Journal Of Molecular Sciences, 2023)

Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease - Soleto, I; Ramirez, C; Gómez, C; Baldan-Martin, M; Orejudo, M; Mercado, J; Chaparro, M; Gisbert, JP (Biomedicines, 2023)

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease - Gisbert, JP; Chaparro, M (Drugs, 2023)

Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013?2022: Data from the European Registry on H. pylori Management (Hp-EuReg) - Nyssen, OP; Pratesi, P; Spinola, MA; Jonaitis, L; Pérez-Aísa, A; Vaira, D; Saracino, IM; Pavoni, M; Fiorini, G; Tepes, B; Bordin, DS; Voynovan, I; et al. (Antibiotics, 2023)

Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg) - Perez-Aisa, A; Nyssen, OP; Keco-Huerga, A; Rodrigo, L; Lucendo, AJ; Gomez-Rodriguez, BJ; Ortuño, J; Perona, M; Huguet, JM; Núñez, O; Fernandez-Bermejo, L; Barrio, J; et al. (Gut, 2023)

ECCO Topical Review on Biological Treatment Cycles in Crohn's Disease - Noor, NM; Sousa, P; Bettenworth, D; Gomollon, F; Lobaton, T; Bossuyt, P; Casanova, MJ; Ding, NS; Dragoni, G; Furfaro, F; van Rheenen, PF; Chaparro, M; et al. (Journal Of Crohns & Colitis, 2023)

Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management - García-Morales, N; Pérez-Aísa, A; Fiorini, G; Tepes, B; Castro-Fernández, M; Lucendo, A; Voynovan, I; Bujanda, L; Garre, A; Rodrigo, L; Domínguez, SJM; Denkovski, M; et al. (Journal Of Clinical Medicine, 2023)

Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP - de Célix, CR; Martín-de-Carpi, J; Pujol-Muncunill, G; Palomino, LM; Rodríguez-Belvís, MV; Martín-Masot, R; Navas-López, VM; Ricart, E; Casanova, MJ; Rodríguez-Martínez, A; Leo-Carnerero, E; Alcaraz, A; et al. (Journal Of Clinical Medicine, 2023)

Rescue therapies for steroid-refractory acute severe ulcerative colitis: A review - Gisbert, JP; Garcia, MJ; Chaparro, M (Journal Of Crohns & Colitis, 2023)

Long-term outcomes of biological therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU - Acosta, MBD; Fernández-Clotet, A; Mesonero, F; García-Alonso, FJ; Casanova, MJ; Fernández-de la Varga, M; Cañete, F; de Castro, L; Gutiérrez, A; Sicilia, B; Cano, V; Merino, O; et al. (American Journal Of Gastroenterology, 2023)

Vaccines in children exposed to biological agents in utero and/or during breastfeeding: are they effective and safe? - Gisbert, JP; Chaparro, M (Journal Of Crohns & Colitis, 2023)

Systematic Review: Urine Biomarker Discovery for Inflammatory Bowel Disease Diagnosis - Baldan-Martin, M; Chaparro, M; Gisbert, JP (International Journal Of Molecular Sciences, 2023)

Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial - Panés, J; Vermeire, S; D'Haens, GR; Danese, S; Magro, F; Nazar, M; Le Bars, M; Lahaye, M; Ni, L; Bravatà, I; Gaya, DR; Peyrin-Biroulet, L; et al. (United European Gastroenterology Journal, 2023)

The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission - Burisch, J; Zhao, M; Odes, S; De Cruz, P; Vermeire, S; Bernstein, CN; Kaplan, GG; Duricova, D; Greenberg, D; Melberg, HO; Watanabe, M; Ahn, HS; et al. (Lancet Gastroenterology & Hepatology, 2023)

Development of a Prediction Model for Short-Term Remission of Patients with Crohn?s Disease Treated with Anti-TNF Drugs - Medina-Medina, R; Iglesias-Flores, E; Benítez, JM; Marín-Pedrosa, S; Salgueiro-Rodríguez, I; Linares, CI; González-Rubio, S; Soto-Escribano, P; Gros, B; Rodríguez-Perálvarez, ML; Cabriada, JL; Chaparro, M; et al. (International Journal Of Molecular Sciences, 2023)

Empiric use of standard triple therapy in Helicobacter pylori eradication does not require readjustment in the clarithromycin resistance cut- off point - Malfertheiner, P; Megraud, F; Rokkas, T; Gisbert, JP (Gut, 2023)

Tips and guidelines for being a good peer reviewer - Gisbert, JP; Chaparro, M (Gastroenterologia Y Hepatologia, 2023)

Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study - I Guerra Marina; L Bujanda; M Manosa; I Pérez-Martinez; MJ Casanova; L de la Pena; M de Benito; M Rivero; P Varela; L Bernal; AC Franco; Y Ber; et al. (Cancers, 2023)

Ex vivo effects of infliximab on the long non-coding RNAs expression levels in Crohn's disease - Baldan-Martin, M; de Célix, CR; Orejudo, M; Ortega, L; Fernández-Tomé, S; Soleto, I; Ramírez, C; Arroyo, R; Fernández, P; Santander, C; Moreno-Monteagudo, JA; Casanova, MJ; et al. (Journal Of Crohns & Colitis, 2023)

The Costs of Inflammatory Bowel Diseases in High-Income Settings - J Burisch; M Zhao; S Odes; P De Cruz; S Vermeire; CN Bernstein; GG Kaplan; D Duricova; D Greenberg; HO Melberg; M Watanabe; HS Ahn; et al. (Journal Of Crohns & Colitis, 2023)

HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry - Sard, MC; Súria, C; Mesonero, F; de Francisco, R; Caballero, CY; de la Peña, L; Hernández-Camba, A; Marcè, A; Gallego, B; Martín-Vicente, N; Rivero, M; Iborra, M; et al. (Journal Of Crohns & Colitis, 2023)

Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT) - Chaparro, M; Donday, MG; Riestra, S; Lucendo, AJ; Benitez, JM; Navarro-Llavat, M; Barrio, J; Morales-Alvarado, VJ; Rivero, M; Busquets, D; Carnerero, EL; Ochoa, OM; et al. (Journal Of Crohns & Colitis, 2023)

Diagnosis, management, and evolution of acute pancreatitis secondary to thiopurines in patients with Inflammatory Bowel Disease: an ENEIDA registry study. - I Guerra Marina; F Barros; F Mesonero; R de Francisco; F Canete; JM Benitez; B Sicilia; MD Martin Arranz; L de Castro; AY Carbajo; A Gutiérrez; M Calvo; et al. (Journal Of Crohns & Colitis, 2023)

Predictive pharmacogenetic risk of pancreatitis in Inflammatory Bowel Disease patients treated with thiopurines: a case-control study from the ENEIDA registry - I Guerra Marina; F Barros; M Chaparro; JM Benitez; MD Martin Arranz; R de Francisco; M Piqueras; L de Castro; AY Carbajo; F Bermejo; M Minguez; A Gutiérrez; et al. (Journal Of Crohns & Colitis, 2023)

Impact of cancer therapy on the course of Inflammatory Bowel Disease (ONCOEII study of GETECCU) - P Pérez Galindo; JM Benitez; C Rubin de Célix; F Mesonero; A Castano Garcia; MJ Garcia; M Vicuna; L Bernal; F Bertoletti; C Ramirez Castro; M Sanchez-Azofra; L Sanchez-Delgado; et al. (Journal Of Crohns & Colitis, 2023)

Effects of anti-TNF and anti-interleukins 12 and 23 drugs on circulating dendritic cells migratory capacity in inflammatory bowel disease - Soleto, I; Ramirez, C; Gómez, C; Montse, B; García, S; Orejudo, M; Mecado, J; Chaparro, M; Gisbert, JP (Journal Of Crohns & Colitis, 2023)

Proteomic characterization of serum extracellular vesicles from newly diagnosed patients with inflammatory bowel disease - Soleto, I; Baldan, M; Ramírez, C; Orejudo, M; García, S; Mercado, J; Azkargorta, M; Lloro, I; Moreno, LO; Garcia, LA; Riestra, S; Rivero, M; et al. (Journal Of Crohns & Colitis, 2023)

Identification of urine and serum diagnostic biomarkers of inflammatory bowel disease using a proteomic approach - M Baldan-Martin; M Azkargorta; I Lloro; I Soleto Fernandez; M Orejudo; C Ramirez; S Garcia; J Mercado; S Riestra; M Rivero; A Gutiérrez; I Rodriguez-Lago; et al. (Journal Of Crohns & Colitis, 2023)

Analysis of intestinal tissue from newly diagnosed patients with inflammatory bowel disease reveals distinct proteomic profiles - M Baldan-Martin; I Lloro; M Azkargorta; C Ramirez; I Soleto Fernandez; M Orejudo; S Garcia; J Mercado; CH Gordillo; S Riestra; M Rivero; A Gutiérrez; et al. (Journal Of Crohns & Colitis, 2023)

COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS ANTI-TNFs IN ULCERATIVE COLITIS BIO-NAIVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF? (EVOLVE-IBERIA STUDY) - Jorda, FC; Rodríguez, C; Gisbert, JP; Bernardo, S; Aparicio, J; Tagarro, I; Muñoz, F (Journal Of Crohns & Colitis, 2023)

Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding - M Chaparro; M Garcia Donday; S Rubio; C Calvino Suarez; A Nunez Ortiz; M Figueira; S Marin Pedrosa; M Rivero; A Fernandez-Clotet; L Madero; MT Diz-Lois Palomares; I Pérez-Martinez; et al. (Journal Of Crohns & Colitis, 2023)

A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence - Dignass, A; Gisbert, JP; Bossa, F; Kelly, O; Rahman, M; Lobatón, T; Addison, J (Journal Of Crohns & Colitis, 2023)

Early predictors of the need for surgery in patients with acute severe ulcerative colitis: results of the prospective, observational, international ESCP MASC study - M Frasson; T Pinkney; JP Gisbert; I Rodriguez-Lago; S Blackwell; KB Gecse; CJ Buskens; C Knowles; O Zamora; M Brookes; G Fiorino; P Nos; et al. (Journal Of Crohns & Colitis, 2023)

Impaired antibody seroconversion after COVID-19 vaccination and negative impact of immunosuppressive treatment in Inflammatory Bowel Disease. Results from a multicentre, prospective study of GETECCU (VACOVEII) - Julián, AB; Casas-Deza, D; Vicente-Lidón, R; Beltrán, B; Domènech, E; Gutiérrez-Casbas, A; Mañosa, M; Zabana, Y; Caudevilla-Biota, E; Corsino-Roche, P; Sierra-Moros, E; Franco-Fobe, LE; et al. (Journal Of Crohns & Colitis, 2023)

Psoriasis induced by anti-TNF therapy in Inflammatory Bowel Disease: analysis of therapeutic management and evolution of both diseases in a nationwide cohort study - P Sanz Segura; F Gomollon; S Garcia Garcia; M Vela; A Fernandez-Clotet; R Munoz; I Garcia de la Filia; M Garcia Prada; JA Ferrer Rosique; MJ Garcia; R de Francisco; L Arias; et al. (Journal Of Crohns & Colitis, 2023)

Immunological effects of hepatitis B virus vaccination in inflammatory bowel disease patients - I Soleto, M Baldan, C Ramirez, M Orejudo, S Garcia, J Mercado, M Azkargorta, I Lloro, L Ort; 17/S1: i27-i29 I Soleto, A C Marin, I Mora, JR Villagrasa, M Baldan-Martin, C Ramírez, D B (Journal Of Crohns & Colitis, 2023)

Efectiveness And Safety Of Ustekinumab In Elderly Patients With Crohn's Disease: Real World Evidence From The Eneida Registry - Casas-Deza D, Lamuela-Calvo LJ, Gomollón F, Arbonés-Mainar JM, Caballol B, Gisbert JP, Rivero M, Sánchez-Rodríguez E, Arias García L, Gutiérrez Casbas A, Merino O, Márquez L, Laredo V, Martín-Arranz MD, López Serrano P, Riestra Menéndez S, González-Muñoza C, de Castro Parga L, Calvo Moya M, Fuentes-Valenzuela E, Esteve M, Iborra M, Dura Gil M, Barreiro-De Acosta M, Lorente-Poyatos RH, Manceñido N, Calafat M, Rodríguez-Lago I, Guardiola Capo J, Payeras MA, Morales Alvarado VJ, Tardillo C, Bujanda L, Muñoz-Nuñez JF, Ber Nieto Y, Bermejo F, Almela P, Navarro-Llavat M, Martínez Montiel P, Rodríguez Gutiérrez C, Van Domselaar M, Sesé E, Martínez Pérez T, Ricart E, Chaparro M, García MJ, López-Sanromán A, Sicilia B, Orts B, López-García A, Martín-Arranz E, Pérez-Calle JL, de Francisco R, García-Planella E, Domènech E, García-López YS (Journal Of Crohns & Colitis, 2023)

I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease - Peyrin-Biroulet, L; Rahier, JF; Kirchgesner, J; Abitbol, V; Shaji, S; Armuzzi, A; Karmiris, K; Gisbert, JP; Bossuyt, P; Helwig, U; Burisch, J; Yanai, H; et al. (Clinical Gastroenterology And Hepatology, 2023)

Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management - Gatta L, Nyssen OP, Fiorini G, Saracino IM, Pavoni M, Romano M, Gravina AG, Granata L, Pellicano R, Gasbarrini A, Di Leo A, Losurdo G, Franceschi F, Nardone G, Rocco A, Dore MP, Farinati F, Ghisa M, Bellini M, Holton J, Puig I, Vaira D, Borghi C, Mégraud F, O'Morain C, Gisbert JP (United European Gastroenterology Journal, 2023)

Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry - Mañosa M, Fernández-Clotet A, Nos P, Martín-Arranz MD, Manceñido N, Carbajo A, Hinojosa E, Hernández-Camba A, Muñoz-Pérez R, Boscá-Watts M, Calvo M, Sierra-Ausín M, Sánchez-Rodríguez E, Barreiro-de Acosta M, Núñez-Alonso A, Zabana Y, Márquez L, Gisbert JP, Guardiola J, Sáinz E, Delgado-Guillena P, Busquets D, van Domselaar M, Girona E, Lorente R, Casas-Deza D, Huguet JM, Maestro S, Cabello MJ, Castro J, Iborra M, Cañete F, Calafat M, Domènech E, ENEIDA registry by GETECCU (Digestive And Liver Disease, 2023)

Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety - Chaparro, M; Acosta, D; Rodríguez, C; Mesonero, F; Vicuña, M; Barreiro-de Acosta, M; Fernández-Clotet, A; Martínez, AH; Arroyo, M; Vera, I; Ruiz-Cerulla, A; Sicilia, B; et al. (American Journal Of Gastroenterology, 2023)

Effectiveness of empirical Helicobacter pylori eradication therapy with furazolidone in Russia: results from the European Registry on Helicobacter pylori Management (Hp-EuReg) - Bordin, DS; Voynovan, IN; Sarsenbaeva, AS; Zaytsev, OV; Abdulkhakov, RA; Bakulina, NV; Bakulin, IG; Osipenko, MF; Livzan, MA; Alekseenko, SA; Tarasova, LV; Tarasova, GN; et al. (Terapevticheskii Arkhiv, 2023)

Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD) - Bokemeyer, B; Hlavaty, T; Allez, M; Selema, P; Moosavi, S; Cadatal, MJ; Fowler, H; Mueller, M; Liau, KF; Gisbert, JP (Expert Opinion On Biological Therapy, 2023)

Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg) - Burgos-Santamaria, Diego; Nyssen, Olga P.; Gasbarrini, Antonio; Vaira, Dino; Perez-Aisa, Angeles; Rodrigo, Luis; Pellicano, Rinaldo; Keco-Huerga, Alma; Pabon-Carrasco, Manuel; Castro-Fernandez, Manuel; Boltin, Doron; Barrio, Jesus; et al. (Gut, 2023)

Current trends in the management of Helicobacter pylori infection in Serbia: preliminary results from the European registry on H. pylori management (Hp-EuReg) - Milivojevic, Vladimir; Babic, Ivana; Kekic, Dusan; Rankovic, Ivan; Sagdati, Sabir; Panic, Nikola; Spasic, Izabela Sekulic; Krstic, Miodrag; Milosavljevic, Tomica; Moreira, Leticia; Perez Nyssen, Olga; Megraud, Francis; et al. (Digestive Diseases, 2023)

FiLaC® procedure for highly selected anal fistula patients: indications, safety and efficacy from an observational study at a tertiary referral center - Blanco Terés, Lara; Bermejo Marcos, Elena; Cerdán Santacruz, Carlos; Correa Bonito, Alba; Rodríguez, Ana; Chaparro Sánchez, María; Pérez Gisbert, Javier; García Septiem, Javier; Martín Pérez, Elena (Revista Espanola De Enfermedades Digestivas, 2023)

Reglas y consejos para ser un buen revisor por pares de manuscritos científicos - Pérez Gisbert, Javier; Chaparro, María (Gastroenterologia Y Hepatologia, 2023)

Co-20. Impacto del uso de probióticos en los resultados del tratamiento erradicador para la infección por helicobacter pylori: Datos del registro europeo (hp-eureg) en andalucia - Pérez Aisa, Ángeles; Rivas Ruiz, Francisco; Gómez Rodríguez, Blas José; Fernández de Castro, M; Perona Alvaro, M; Parra-Membrives, Pablo; Cano Catalá, A; Keco Huerga, Alma; Hernández, L; Moreira, L; Nyssen, O; Pérez Gisbert, Javier (Revista Andaluza De Patología Digestiva, 2023)

Co-24. Optimizacion de la dosis de los inhibidores de la bomba de protones en los tratamientos erradicadores de primera y segunda linea frente a helicobacter pylori: Resultados del registro europeo sobre el manejo de la infección por helicobacter pylori (hp-eureg) - A Keco-Huerga; M Pabón-Carrasco; M Castro-Fernández; I Maria Saracino; G Fiorini; D Vaira; A Pérez-Aísa; B Tepes; L Jonaitis; I Voynovan; A J Lucendo; A Lanas; et al. (Revista Andaluza De Patología Digestiva, 2023)

EU4H-2022-PJ Project number: 101101252. Towards gastric cancer screening implementation in the european union (TOGAS project). Investigador Principal Work Package 5 - Perez Gisbert, Francisco Javier (Investigador/a) (2023)

Efecto del tratamiento combinado con agentes biológicos en comparación con la monoterapia en un modelo murino de EII (MICEBINE). Asociación Española de Gastroenterología. Beca Grupo de Trabajo EII. Investigador Principal del Grupo Receptor - Perez Gisbert, Francisco Javier (Investigador/a) (2023)

HORIZON-HLTH-2022-STAYHLTH-02 HORIZON-RIA 101095359. An Artificially Intelligent Diagnostic Assistant for gastric inflammation. (AIDA project). Investigador Principal Work Package 2 - Perez Gisbert, Francisco Javier (Investigador/a) (2023)

INT22/00099. Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud. ISCIII. Investigador Principal - Perez Gisbert, Francisco Javier (Investigador/a) (2023)

PI22/01069 (FIS). Estudio comparativo del efecto inmunomodulador de la combinacio?n de fa?rmacos biolo?gicos en la enfermedad inflamatoria intestinal (COMBINE). Investigador Principal Senior Grupo Receptor/Asesor - Perez Gisbert, Francisco Javier (Investigador/a) (2023)

Proteomic approach to identify predictive biomarkers of relapse after anti-TNF discontinuation in inflammatory bowel disease. Asociación Española de Gastroenterología. Beca Gonzalo Miño. Investigador Principal del Grupo Receptor - Perez Gisbert, Francisco Javier (Investigador/a) (2023)

Validación de marcadores indentificados mediante proteómica en biopsias intestinales para su potencial aplicación clínica enla enfermedad inflamatoria intestinal. Beca GETECCU Investigación básica. IP Grupo Receptor - Perez Gisbert, Francisco Javier (Investigador/a) (2023)

A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week análisis of persistence. Journal of Crohn and Colitis - A Dignass; JP Gisbert; F Bossa; O Kelly; M Rahman; T Lobaton; J Addison (2023)

Actualización en el manejo de la infección por Helicobacter pylori en Andalucía: datos del Registro Europeo (Hp-EuReg) en primera línea de tratamiento. Seleccionada para comunicación oral. - MD García García; J González Antuna; BJ Gómez Rodríguez; A Pérez-Aisa; M Pabón-Carrasco; M Castro-Fernández; M Perona; A Keco-Huerga; A Cano-Catalá; L Hernández; L Moreira; O Nyssen; et al. (2023)

An artificially intelligent diagnostic assistant for gastric inflammation (AIDA). - J P Gisbert; O P Nyssen; A Miralles-Marco; E Jiménez; M Leja; F Carneiro; C Figueiredo; L Moreira; T Matysiak-Budnik; J Martin; J Kup?inskas; M Dinis-ribeiro; et al. (2023)

Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU. Seleccionada para comunicación oral. - C Rubín de Célix; J Martín de Carpi; G Pujol Muncunill; LM Palomino Pérez; M Velasco Rodríguez-Belvís; R Martín-Masot; VM Navas-López; E Ricart; MJ Casanova; A Rodríguez Martínez; E Leo Carnerero; A Alcaraz; et al. (2023)

Biological Treatment Cycles in Crohn?s Disease. Digital oral presentations. - N Noor; P Sousa; D Bettenworth; F Gomollon; T Lobaton; P Bossuyt; MJ Casanova; N Ding; G Dragoni; F Furfaro; P van Rheenen; M Chaparro; et al. (2023)

Brazilian registry on H. pylori management (Hp-BrazilReg): analysis of 640 first-line treatments. - B S F Sanches; O P Nyssen; L T Ribeiro; J C S Veloso; S R Chaves; H P Breyer; H Okamoto; J R Marinho; G C Couto; L F Guidi; C S Alencar; L A S Sousa; et al. (2023)

Caracterización proteómica de las vesículas extracelulares séricas de pacientes recién diagnosticados de enfermedad inflamatoria intestinal. Seleccionada para comunicación oral. - I Soleto, M Baldan-Martín, C Ramírez, M Orejudo, S García, J Mercado, M Azkargorta, I Iloro, L Orteg; Ber, D Ginard, M Esteve, F Elortza, JP Gisbert, Noa Martín-Cofreces; Maria Chaparro (2023)

Clinical phenotypes through machine learning of first-line treated patients during the period 2013-2022: data from the European registry on Helicobacter pylori management (Hp-EuReg). - O P Nyssen; M Spinola; P Pratesi; G J Ortega2; L Jonaitis; Á Pérez-Aísa; D Vaira; G Fiorini; B Tepes; D S Bordin; M Leja; F Lerang; et al. (2023)

Efectividad en primera línea de tratamiento frente a Helicobacter pylori: subanálisis de los datos españoles del registro europeo sobre el manejo de la infección por H. pylori (Hp-EuReg). - L Hernández; M A Pérez-Aisa; S Jesús Martínez- Domínguez; M Pabón-Carrasco; L Bujanda; A Lucendo; L Rodrigo; A Garre; J MHuguet; N Alcaide; M Perona; J Barrio; et al. (2023)

Efectividad y seguridad de la terapia con ustekinumab y vedolizumab en pacientes con fístula perianal compleja: Estudio HEAL. - M J Casanova; M Chaparro; B Caballol; M J García; F Mesonero; C Rubín de Célix; P Suárez-Álvarez; R Ferreiro-Iglesias; M M Martín-Rodríguez; R de Francisco; P Varela-Trastoy; G Bastida; et al. (2023)

Efectos de los fármacos anti-TNF y anti-interleucinas 12 y 23 sobre la capacidad migratoria de las células dendríticas circulantes en la enfermedad inflamatoria intestinal. - M Baldán-Martín; C Rubín de Célix; M Orejudo; L Ortega; S Fernández Tomé; I Soleto; C Ramirez; R Arroyo; P Fernández; C Santander; J A Moreno- Monteagudo; M J Casanova; et al. (2023)

Effectiveness of Helicobacter pylori treatments according to antibiotic resistance: results from the European registry on H. pylori management (Hp-EuReg). - L Bujanda; O P Nyssen; J Ramos; D S Bordin; B Tepes; Á Perez-Aisa; M Pavon; M Castro Fernandez; F Lerang; M Leja; L Rodrigo; T Rokkas; et al. (2023)

Effects of anti-TNF and anti-interleukins 2 and 23 drugs on circulating dendritic cells migratory capacity in inflammatory bowel disease. Publicación: Journal of Crohn and Colitis - I Soleto; C Ramirez; C Gomez; B Montse; S Garcia; M Orejudo; J Mecado; M Chaparro; JP Gisbert (2023)

Eficacia y seguridad de la monitorización proactiva de niveles de fármacos anti-TNF en el tratamiento de mantenimiento de pacientes con enfermedad inflamatoria intestinal: revisión sistemática y metaanálisis. GPublicación: Gastroenterol Hepatol - I Soleto; A C Marín; I Mora; J R Villagrasa; M Baldan-Martín; C Ramirez; D Bernardo; M Chaparro; JP Gisbert Efectos inmunológicos de la vacunación contra el virus de la hepatitis B en pacientes; 46(3): 72 N Manceñido Marcos; B Novella Arribas; G Mora Navarro; et al. (2023)

Eficacia y seguridad del tratamiento de rescate en la colitis ulcerosa corticorrefractaria grave refractaria a infliximab o ciclosporina (Estudio REASUC). Seleccionada para comunicación oral - MJ García; S Riestra; A Amiot; M Julsgaard; I Garcia de la Filia; M Calafat; M Aguas; L de la Pena; C Roig-Ramos; B Caballol; MJ Casanova; K Farkas; et al. (2023)

Eficacia y seguridad del tratamiento de rescate en la colitis ulcerosa corticorrefractaria grave refractaria a infliximab o ciclosporina (Estudio REASUC). Seleccionada para comunicación oral. Premio a la mejor comunicación oral de Enfermedad Inflamatoria Intestinal. - MJ García; S Riestra; A Amiot; M Julsgaard; I García de la Filia; M Calafat; M Aguas; L de la Peña; C Roig-Ramos; B Caballol; M J Casanova; K Farkas; et al. (2023)

El análisis del tejido intestinal de pacientes recién diagnosticados de enfermedad inflamatoria intestinal revela perfiles proteómicos específicos. Publicación: Gastroenterol Hepatol - M Baldán-Martín, I Iloro, M Azkargorta, C Ramirez, I Soleto, M Orejudo, J Mercado, C H Gordillo, S; Ber, V Royo, M Esteve, F Elortza, JP Gisbert; M Chaparro (2023)

Empirical second-line treatments in Europe: results from the European registry on Helicobacter pylori management (Hp-EuReg). - O P Nyssen; D Vaira; I Saracino; M Pavoni; G Fiorini; Á Perez-Aisa; L Jonaitis; M Castro-Fernandez; D Boltin; L Hernández; A Gasbarrini; D S Bordin; et al. (2023)

European registry on Helicobacter pylori management (Hp-EuReg): analysis of 2,254 empirical rescue therapies on third and subsequent lines. - O P Nyssen; D Vaira; I Saracino; M Pavoni; G Fiorini; Á Perez-Aisa; L Jonaitis; M Castro-Fernandez; D Boltin; L Hernández; A Gasbarrini; D S Bordin; et al. (2023)

Experience with single-capsule bismuth quadruple therapy in 8,000 patients from the European registry on Helicobacter pylori management (Hp-EuReg). - O P Nyssen; P Parra; Á Pérez-Aísa; M Castro-Fernandez; M Pabón-Carrasco; A Keco-Huerga; L Rodrigo; Á Lanas; S J Martínez-Domínguez; E Alfaro; A J Lucendo; A Gasbarrini; et al. (2023)

First description of the data from the Latin American registry on the management of Helicobacter pylori infection (Hp-LATAMReg). - D Reyes Placencia; J Remes-Troche; O Laudanno; W Otero; A Piscoya; J Ramírez García; G Otoya; G Latorre; J Chahuan; A Arenas; M Pizarro; F Martinez; et al. (2023)

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study - Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S, GARDENIA Study Group (2022)

Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry - Zabana Y; Marín-Jiménez I; Rodríguez-Lago I; Vera I; Martín-Arranz MD; Guerra I; Gisbert JP; Mesonero F; Benítez O; Taxonera C; Ponferrada-Díaz Á; Piqueras M; et al. (Journal Of Clinical Medicine, 2022)

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment - Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, Karmiris K, Katsanos K, Kopylov U, Lakatos PL, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Spinelli A, Panis Y, Doherty G (Journal Of Crohns & Colitis, 2022)

Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery - M Baldan Martin; M Azkargorta; I Iloro; L Ortega Moreno; L Aldars-García; I Soleto; C Ramírez; S Riestra Menéndez; M Rivero Tirado; A Gutierrez Casbas; I Rodríguez-Lago; L Fernández Salazar; et al. (Journal Of Crohns & Colitis, 2022)

The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn's disease - A Dignass; J Gisbert; U Freudensprung; J Addison (Journal Of Crohns & Colitis, 2022)

Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies - Pauwels RWM; van der Woude CJ; Nieboer D; Steyerberg EW; Casanova MJ; Gisbert JP; Kennedy NA; Lees CW; Louis E; Molnár T; Szántó K; Leo E; et al. (Clinical Gastroenterology And Hepatology, 2022)

Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU - M Chaparro; A Gutiérrez; C Calviño-Suárez; JM Huguet; M Calvo; M Aguas; R Camargo Camero; MÁ de Jorge Turrión; D Hervías Cruz; P López Serrano; S Marín Pedrosa; P Martínez Montiel; et al. (Journal Of Crohns & Colitis, 2022)

Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD) - Garcia, M. J.; Rivero, M.; Fernandez-Clotet, A.; de Francisco, R.; Sicilia, B.; Mesonero, F.; de Castro, M. L.; Casanova, M. J.; Bertoletti, F.; Garcia Alonso, F. J.; Lopez Garcia, A.; Julian, B.; et al. (Journal Of Crohns & Colitis, 2022)

Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry) - M Gonzalez Vivo; M Urpí Ferreruela; B Castro Senosiain; I Pérez-Martínez; J Barrio; L Codesido Prado; B Caballol Oliva; V Pedrera Roman; M Piqueras Cano; F Rodríguez Moranta; MJ Casanova González; L Ramos; et al. (Journal Of Crohns & Colitis, 2022)

Assessment of first-line eradication treatment in Greece: data from the European Registry on Helicobacter pylori management (Hp-EuReg) - Rokkas, T; Georgopoulos, S; Michopoulos, S; Ntouli, V; Liatsos, C; Puig, I; Nyssen, OP; Megraud, F; O'Morain, C; Gisbert, JP (Annals Of Gastroenterology, 2022)

CD21/00014. Programa Sara Borrell. AES. ISCIII. Investigador Principal del Grupo Receptor - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

Comparative study of the immunomodulatory effect of the combination of biologic drugs in inflammatory bowel disease (COMBINE). Janssen-Fundación Encuentros Médico-Quirúrgicos para el estudio de la EII. Investigador Principal - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

Estudio de las causas y consecuencias de la persistencia de atrofia vellositaria a pesar de dieta sin gluten intencionalmente estricta en pacientes con enfermedad celíaca (Estudio CADER 2). Investigador Principal H de La Princesa - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

FJC2020-044317-I. Programa Juan de la Cierva-Incorporación Plan Estatal de Investigación Científica y Técnica y de Innovación (Renuncia por concesión de Sara Borrell). IP Grupo Receptor - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

IR2021-UVA04. Infraestructuras en Red de Castilla y León (INFRARED). Investigador - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

Long-term benefit of ustekinumab in ulcerative colitis in clinical practice. ULISES Study. Janssen Investigator Initiated Sponsored Research. Investigador Principal y Promotor - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

Long-term trends in targeted therapies (biologics and tofacitinib) usage in inflammatory bowel disease: TRENDY study. Galapagos Investigator Initiated Sponsored Research. Investigador Principal y Promotor - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

Long-term trends in targeted therapies (biologics and tofacitinib) usage in inflammatory bowel disease: TRENDY study. IP Grupo Receptor - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

PI21/01086 (FIS). Riesgo trombótico en pacientes con colitis ulcerosa en tratamiento con inhibidores JAK: efecto sobre la función plaquetaria y la cascada de coagulación. Investigador Principal - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

Río Hortega. AES. ISCIII (CM21/00025). Investigador Principal del Grupo Receptor - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

SEPE CAM EXP.09-PIN1-00015.6/2022. Investigador Principal Grupo Receptor - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

SEPE: 2022-C23.I01.P03.S0020-0000031 Programa Investigo-Fondos resiliencia (SEPE INVESTIGO-18 Digestivo). Investigador Principal Grupo Receptor - Perez Gisbert, Francisco Javier (Investigador/a) (2022)

Clinical outcomes after anti-TNF discontinuation in inflammatory bowel disease patients in remission on anti-TNF therapy plus immunosupressants: the EXIT long-term study - Perez Gisbert, Francisco Javier (Otros) (2022)

Efectiveness and safety of a third-line rescue therapy on acute severe ulcerative colitis refractory to infliximab and cyclosporin (REASUC) - Perez Gisbert, Francisco Javier (Otros) (2022)

Effectiveness and safety of vedolizumab and ustekinumab tHerapy for complex pEriAnaL fistula in Crohn?s disease: The HEAL study - Perez Gisbert, Francisco Javier (Otros) (2022)

Enteric iNfecTions in eldeRly patIents hospitalized with inflammaTory bowel diseases flare ? the ENTRIT study group - Perez Gisbert, Francisco Javier (Otros) (2022)

Pandora: a European study about prevalence, clinical management and outcome of acute pancreatitis in inflammatory bowel disease - Perez Gisbert, Francisco Javier (Otros) (2022)

Solid organ transplant (but liver) in patients with inflammatory bowel disease: An ECCO CONFER Multicentre Case Series - Perez Gisbert, Francisco Javier (Otros) (2022)

Third-line therapy in refractory ulcerative colitis: a comparison between tofacitinib and ustekinumab - Perez Gisbert, Francisco Javier (Otros) (2022)

Upadacitinib: real world evidence in inflammatory bowel disease (U-REAL) - Perez Gisbert, Francisco Javier (Otros) (2022)

Comparison of the effectiveness of Helicobacter pylori eradication regimens between the elderly and non-elderly populations: Data from the European registry on H. pylori management (Hp-EuReg). - P Jonaitis; J Kupcinskas; Á Pérez-Aísa; D Vaira; B Tepe?; DS Bordin; M Castro-Fernandez; AJ Lucendo; L Vologzhanina; L Bujanda Fernández de Piérola; M Denkovski; A Lanas; et al. (2022)

Role of compliance in Helicobacter pylori treatments: results from the European registry on H. pylori management (Hp-EuReg). - P Suárez; L Ferrer-Barceló; JM Huguet; Á Pérez-Aísa; B Vaira; LV Jonaitis; B Tepe?; DS Bordin; A Keco-Huerga; AJ Lucendo; L Vologzhanina; L Bujanda Fernández de Piérola; et al. (2022)

Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease. - MJ Casanova; M Chaparro; Ó Nantes; P Varela; M Vela-González; R Montserrat; OG Sierra; S Riestra; M Barreiro-de Acosta; MM Martín-Rodríguez; CJ Gargallo-Puyuelo; C Reygosa; et al. (2022)

Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry. - C González-Muñoza; M Calafat; JP Gisbert; E Iglesias; M Mínguez; B Sicilia; M Esteve; F Gomollon; X Calvet; E Ricart; D Carpio; M Rivero; et al. (2022)

Clinical phenotypes through machine learning of first-line treated patients in europe during the period 2013-2021: data from the European Registry on H. pylori management (Hp-EuReg). Seleccionada como moderated poster - O Perez Nyssen; A Sanz-García; GJ Ortega; JP Gisbert (2022)

Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD). Seleccionada como una de las 10 mejores Digital Oral Presentations - MJ García; M Rivero; A Fernández-Clotet; R de Francisco; B Sicilia; F Mesonero; ML de Castro; MJ Casanova; F Bertoletti; FJ García Alonso; A López García; B Julián; et al. (2022)

Differences of Helicobacter pylori diagnostics and treatment in the elderly and non-elderly populations: data from European registry on H. pylori management (Hp-EuReg). - P Jonaitis; J Kupcinskas; Á Pérez-Aísa; D Vaira; B Tepe?; DS Bordin; M Castro-Fernandez; AJ Lucendo; L Vologzhanina; L Bujanda Fernández de Piérola; M Denkovski; A Lanas; et al. (2022)

Effectiveness and safety of high-dose dual therapy: results of the European Registry on H. pylori management (Hp-EuReg). - L Fernández-Salazar; Á Pérez-Aísa; B Vaira; LV Jonaitis; B Tepe?; DS Bordin; A Keco-Huerga; A Lucendo Villarin; L Vologzhanina; L Bujanda Fernández de Piérola; N Brglez Jurecic; A Lanas; et al. (2022)

Effectiveness and safety of switching from adalimumab reference to biosimilar in patients with inflammatory bowel disease: the Ada-switch Study. - MJ Casanova; M Chaparro Sanchez; Ó Nantes; P Varela; M Vela-González; M Rivero; O Sierra-Gabarda; S Riestra; M Barreiro-de Acosta; MdM Martín-Rodríguez; CJ Gargallo-Puyuelo; C Reygosa; et al. (2022)